Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.

[1]  Y. Kamatani,et al.  Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. , 2023, The New England journal of medicine.

[2]  C. Redfern,et al.  Rucaparib or Physician's Choice in Metastatic Prostate Cancer. , 2023, The New England journal of medicine.

[3]  W. Park,et al.  Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer , 2022, Journal for ImmunoTherapy of Cancer.

[4]  Jianxin Shi,et al.  Rare germline deleterious variants increase susceptibility for lung cancer. , 2022, Human molecular genetics.

[5]  B. Taylor,et al.  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. , 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  N. Lennon,et al.  Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. , 2022, JAMA oncology.

[7]  Shalini Ojha,et al.  The natural history of ataxia-telangiectasia (A-T): A systematic review , 2022, PloS one.

[8]  B. Gyawali,et al.  Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care? , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jaana M. Hartikainen,et al.  Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes , 2022, JAMA oncology.

[10]  D. Kirsch,et al.  Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. , 2022, Seminars in radiation oncology.

[11]  R. Plummer,et al.  A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. , 2021, Lung cancer.

[12]  D. Torigian,et al.  Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. , 2021, Gynecologic oncology.

[13]  W. Park,et al.  Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  E. Kohn,et al.  A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer , 2021, Nature Communications.

[15]  R. Hruban,et al.  Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. , 2021, JAMA oncology.

[16]  M. Milowsky,et al.  Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[17]  Changyu Wang,et al.  WEE1 inhibitor and ataxia telangiectasia and RAD3‐related inhibitor trigger stimulator of interferon gene‐dependent immune response and enhance tumor treatment efficacy through programmed death‐ligand 1 blockade , 2021, Cancer science.

[18]  J. Sklar,et al.  Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations) , 2021, JCO precision oncology.

[19]  J. Soria,et al.  Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study , 2021, Clinical Cancer Research.

[20]  L. Sequist,et al.  Lung cancer , 2021, The Lancet.

[21]  Nina R. Filippone,et al.  Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase. , 2021, Molecular pharmaceutics.

[22]  R. Plummer,et al.  Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours , 2021, British Journal of Cancer.

[23]  R. Plummer,et al.  Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours , 2021, British Journal of Cancer.

[24]  Joon-Oh Park,et al.  Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer , 2021, Clinical Cancer Research.

[25]  G. Curigliano,et al.  Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. , 2021, European journal of cancer.

[26]  David C. Smith,et al.  Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors , 2021, JAMA oncology.

[27]  Marshall W. Anderson,et al.  Rare deleterious germline variants and risk of lung cancer , 2021, npj Precision Oncology.

[28]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[29]  James Y. Dai,et al.  Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study , 2021, European urology oncology.

[30]  O. Arrieta,et al.  Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.

[31]  J. Ngeow,et al.  Identifying ataxia‐telangiectasia in cancer patients: Novel insights from an interesting case and review of literature , 2020, Clinical case reports.

[32]  K. Stopsack,et al.  Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. , 2020, European urology.

[33]  P. Nelson,et al.  Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Delteil,et al.  ATM antagonizes NHEJ proteins assembly and DNA-ends synapsis at single-ended DNA double strand breaks , 2020, Nucleic acids research.

[35]  M. Spies,et al.  Dynamic elements of replication protein A at the crossroads of DNA replication, recombination, and repair , 2020, Critical reviews in biochemistry and molecular biology.

[36]  M. Lavin,et al.  Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management , 2020, Expert review of clinical immunology.

[37]  Run-Chang Wang,et al.  ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer. , 2020, Pathology, research and practice.

[38]  M. Zelefsky,et al.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. , 2020, Journal of the National Cancer Institute.

[39]  Tao Wang,et al.  DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden , 2020, Cell reports medicine.

[40]  N. Tunariu,et al.  Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Kohn,et al.  Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[42]  E. Antonarakis.  Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one? , 2020, Nature Reviews Clinical Oncology.

[43]  M. S. Artigas,et al.  Protein-altering germline mutations implicate novel genes related to lung cancer development , 2020, Nature Communications.

[44]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[45]  A. Cherniack,et al.  Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[46]  Tao Hu,et al.  ATM gene polymorphisms are associated with poor prognosis of non-small cell lung cancer receiving radiation therapy , 2020, Aging.

[47]  Zuhua Chen,et al.  Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort , 2020, Annals of translational medicine.

[48]  M. Zauderer,et al.  Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk , 2020, medRxiv.

[49]  Lele Song,et al.  The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility , 2020, Translational lung cancer research.

[50]  C. D. Dela Cruz,et al.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention. , 2020, Clinics in chest medicine.

[51]  F. Feng,et al.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.

[52]  L. Fu,et al.  ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells , 2020, Medical Molecular Morphology.

[53]  R. Rosell,et al.  Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. , 2020, Critical reviews in oncology/hematology.

[54]  B. P. Van de Warrenburg,et al.  Classic ataxia-telangiectasia: the phenotype of long-term survivors , 2019, Journal of Neurology.

[55]  X. Yi,et al.  Clinical and genomic features of Chinese lung cancer patients with germline mutations , 2019, Nature Communications.

[56]  T. Dörk,et al.  Functional classification of ATM variants in ataxia‐telangiectasia patients , 2019, Human mutation.

[57]  E. Antonarakis,et al.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.

[58]  X. Yi,et al.  Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.

[59]  Y. Taki,et al.  Diversity of ATM gene variants: a population-based genome data analysis for precision medicine , 2019, Human Genomics.

[60]  Eric A. Miller,et al.  Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team 1. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  T. Lawrence,et al.  Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. , 2019, Cancer research.

[62]  Jingsong Zhang,et al.  Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand , 2019, Journal of Hematology & Oncology.

[63]  G. Corrao,et al.  Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  T. Dörk,et al.  Genotype–phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations , 2019, Journal of Medical Genetics.

[65]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[66]  L. Bottolo,et al.  Genotype, extrapyramidal features, and severity of variant ataxia‐telangiectasia , 2018, Annals of neurology.

[67]  J. Barrett,et al.  PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer , 2018, Oncoimmunology.

[68]  N. Altorki,et al.  The lung microenvironment: an important regulator of tumour growth and metastasis , 2018, Nature Reviews Cancer.

[69]  M. van Deuren,et al.  Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia , 2018, Neurology.

[70]  G. Mills,et al.  State-of-the-art strategies for targeting the DNA damage response in cancer , 2018, Nature Reviews Clinical Oncology.

[71]  J. R. Paulson,et al.  An intrinsic S/G2 checkpoint enforced by ATR , 2018, Science.

[72]  A. Cardona,et al.  Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients , 2018, Oncotarget.

[73]  Fengtang Yang,et al.  ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks , 2018, bioRxiv.

[74]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[75]  G. Mills,et al.  Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers , 2018, Nature Communications.

[76]  A. Aghamohammadi,et al.  Inflammation, a significant player of Ataxia–Telangiectasia pathogenesis? , 2018, Inflammation Research.

[77]  J. Bartek,et al.  Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis , 2018, Oncogene.

[78]  H. Fan,et al.  Association between ATM gene polymorphisms, lung cancer susceptibility and radiation-induced pneumonitis: a meta-analysis , 2017, BMC Pulmonary Medicine.

[79]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[80]  F. Couch,et al.  Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. , 2017, Gynecologic oncology.

[81]  S. E. Stanley,et al.  Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[82]  Wei Li,et al.  A meta-analysis of the relationship between ataxia-telangiectasia mutated gene polymorphisms and lung cancer susceptibility. , 2017, Pathology, research and practice.

[83]  T. Cai,et al.  Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies , 2017, Scientific Reports.

[84]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[85]  Alexander Gutin,et al.  Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. , 2017, JCO precision oncology.

[86]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[87]  Y. Bossé,et al.  A Decade of GWAS Results in Lung Cancer , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[88]  A. Etzioni,et al.  Ataxia-telangiectasia: Immunodeficiency and survival. , 2017, Clinical immunology.

[89]  S. Lees-Miller,et al.  Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC , 2017, Oncotarget.

[90]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[91]  N. Mahlaoui,et al.  Treatment of acute leukemia in children with ataxia telangiectasia (A-T). , 2016, European journal of medical genetics.

[92]  T. Crawford,et al.  Ataxia telangiectasia: a review , 2016, Orphanet Journal of Rare Diseases.

[93]  A. Ryan,et al.  Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer , 2016, Oncotarget.

[94]  A. Taylor,et al.  Health risks for ataxia‐telangiectasia mutated heterozygotes: a systematic review, meta‐analysis and evidence‐based guideline , 2016, Clinical genetics.

[95]  T. Zeng,et al.  Effect of ATM-111 (G>A) Polymorphism on Cancer Risk: A Meta-Analysis. , 2016, Genetic testing and molecular biomarkers.

[96]  T. Kipps,et al.  ATM Mutations in Cancer: Therapeutic Implications , 2016, Molecular Cancer Therapeutics.

[97]  W. Han,et al.  Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer , 2016, Breast Cancer Research and Treatment.

[98]  J. Siegfried,et al.  ATM protein is deficient in over 40% of lung adenocarcinomas , 2016, Oncotarget.

[99]  J. Cui,et al.  Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy , 2016, Medicine.

[100]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[101]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[102]  Li Ding,et al.  Patterns and functional implications of rare germline variants across 12 cancer types , 2015, Nature Communications.

[103]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[104]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[105]  T. Stracker,et al.  ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion , 2015, eLife.

[106]  H. Katoh,et al.  Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer , 2015, Mediators of inflammation.

[107]  T. Gasser,et al.  Clinical variability in ataxia–telangiectasia , 2015, Journal of Neurology.

[108]  S. Lees-Miller,et al.  Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer , 2015, Breast Cancer Research.

[109]  Fengjiao Tang,et al.  Ataxia telangiectasia-mutated gene polymorphisms and acute normal tissue injuries in cancer patients after radiation therapy: a systematic review and meta-analysis. , 2015, International journal of radiation oncology, biology, physics.

[110]  P. Byrd,et al.  Ataxia telangiectasia: more variation at clinical and cellular levels , 2015, Clinical genetics.

[111]  F. Alt,et al.  Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination , 2015, Microbiology spectrum.

[112]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[113]  Kai Li,et al.  DNA repair pathway genes and lung cancer susceptibility: a meta-analysis. , 2014, Gene.

[114]  M. Hudson,et al.  Pilot study of modified LMB‐based therapy for children with ataxia–telangiectasia and advanced stage high grade mature B‐cell malignancies , 2014, Pediatric blood & cancer.

[115]  N. Amariglio,et al.  Acute Lymphoblastic Leukemia in Early Childhood as the Presenting Sign of Ataxia-Telangiectasia Variant , 2013, Pediatric hematology and oncology.

[116]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[117]  Hongliang Liu,et al.  ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[118]  Y. Shiloh,et al.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more , 2013, Nature Reviews Molecular Cell Biology.

[119]  D. Kerr,et al.  Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN , 2012, Oncotarget.

[120]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[121]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[122]  H. Morgenstern,et al.  Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. , 2012, European journal of cancer.

[123]  Rebecca M. Jones,et al.  Replication fork dynamics and the DNA damage response. , 2012, The Biochemical journal.

[124]  A. Broeks,et al.  Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia‐telangiectasia: A genotype–phenotype study , 2012, Human mutation.

[125]  G. Stewart,et al.  Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia , 2011, British Journal of Cancer.

[126]  Anjali Sharma,et al.  Ataxia telangiectasia: A report of two cousins and review of literature , 2011, Indian Journal of Medical and Paediatric Oncology.

[127]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[128]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[129]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype , 2011 .

[130]  D. Easton,et al.  Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours , 2011, British Journal of Cancer.

[131]  W. Tan,et al.  Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[132]  W. Tan,et al.  ATM polymorphisms are associated with risk of radiation-induced pneumonitis. , 2010, International journal of radiation oncology, biology, physics.

[133]  Yuh-Shan Jou,et al.  ATM polymorphisms and risk of lung cancer among never smokers. , 2010, Lung cancer.

[134]  T. Morio,et al.  Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan , 2009, International journal of hematology.

[135]  Maria Teresa Landi,et al.  Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer , 2009, International journal of cancer.

[136]  M. D. Del Bigio,et al.  Ataxia-Telangiectasia: Atypical Presentation and Toxicity of Cancer Treatment , 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[137]  C. Punt,et al.  Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array , 2009, British Journal of Cancer.

[138]  D. Schatz,et al.  RAG1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci , 2009, Nature Immunology.

[139]  M. Lavin,et al.  Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer , 2008, Nature Reviews Molecular Cell Biology.

[140]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[141]  P. Byrd,et al.  Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene , 2008, Clinical and experimental immunology.

[142]  M. Greene,et al.  Concise handbook of familial cancer susceptibility syndromes - second edition. , 2008, Journal of the National Cancer Institute. Monographs.

[143]  B. Kang,et al.  Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. , 2008, Mutation research.

[144]  T. Illig,et al.  Detection of ATM gene mutations in young lung cancer patients: a population-based control study. , 2008, Archives of medical research.

[145]  A. Børresen-Dale,et al.  Alpha fetoprotein is increasing with age in ataxia-telangiectasia. , 2007, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[146]  Peng Liu,et al.  Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. , 2007, Lung cancer.

[147]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[148]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  K. Hess,et al.  Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Yun-Chul Hong,et al.  Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. , 2006, Human molecular genetics.

[151]  R. Gatti,et al.  ATM Gene Founder Haplotypes and Associated Mutations in Polish Families with Ataxia‐Telangiectasia , 2005, Annals of human genetics.

[152]  T. Eisen,et al.  Systematic review of the relationship between family history and lung cancer risk , 2005, British Journal of Cancer.

[153]  L. Hutchins,et al.  Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System , 2005, Clinical Cancer Research.

[154]  T. Crawford,et al.  Survival probability in ataxia telangiectasia , 2005, Archives of Disease in Childhood.

[155]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[156]  D. Stoppa-Lyonnet,et al.  Cancer risk according to type and location of ATM mutation in ataxia‐telangiectasia families , 2005, Genes, chromosomes & cancer.

[157]  D. Gudbjartsson,et al.  Familial risk of lung carcinoma in the Icelandic population. , 2004, JAMA.

[158]  Marshall W. Anderson,et al.  A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.

[159]  T. Crawford,et al.  Immunodeficiency and infections in ataxia-telangiectasia. , 2004, The Journal of pediatrics.

[160]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[161]  O. Sanal,et al.  Comprehensive scanning of the ATM gene with DOVAM‐S , 2003, Human mutation.

[162]  T. Stankovic,et al.  ATM Mutations in Sporadic Lymphoid Tumours , 2002, Leukemia & lymphoma.

[163]  A. Aurias,et al.  Cancer risk in heterozygotes for ataxia‐telangiectasia , 2001, International journal of cancer.

[164]  J. Boultwood.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma , 2001, Journal of clinical pathology.

[165]  M. Swift,et al.  Mortality Rates among Carriers of Ataxia-Telangiectasia Mutant Alleles , 2000, Annals of Internal Medicine.

[166]  J. Hall,et al.  The ATM gene and breast cancer: is it really a risk factor? , 2000, Mutation research.

[167]  J. Klijn,et al.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. , 2000, American journal of human genetics.

[168]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[169]  H. Kantarjian,et al.  Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. , 1998, Cancer research.

[170]  I. Vořechovský,et al.  ATM is usually rearranged in T-cell prolymphocytic leukaemia , 1998, Oncogene.

[171]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[172]  A. S. Graaf,et al.  An early-onset recessive cerebellar disorder with distal amyotrophy and, in two patients, gross myclonia: a probable ataxia telangiectasia variant , 1995, Clinical Neurology and Neurosurgery.

[173]  J. Bodensteiner,et al.  Cerebral White-Matter Changes Suggesting Leukodystrophy in Ataxia Telangiectasia , 1994, Journal of child neurology.

[174]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[175]  D. Weeks,et al.  Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia. , 1991, Radiation research.

[176]  A. Taylor,et al.  Unusual features in the inheritance of ataxia telangiectasia , 1990, Human Genetics.

[177]  M. Swift,et al.  Cancer predisposition of ataxia-telangiectasia heterozygotes. , 1990, Cancer genetics and cytogenetics.

[178]  F. Hecht,et al.  Cancer in ataxia-telangiectasia patients. , 1990, Cancer genetics and cytogenetics.

[179]  C. Naspitz,et al.  Ataxia-telangiectasia: a clinical and laboratory review study of 14 cases. , 1990, Allergologia et immunopathologia.

[180]  R. Gatti,et al.  Tissue specificity of chromosomal rearrangements in ataxia-telangiectasia , 1989, Human Genetics.

[181]  M. Green,et al.  Comparative human cellular radiosensitivity: II. The survival following gamma-irradiation of unstimulated (G0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and from ataxia-telangiectasia heterozygotes. , 1988, International journal of radiation biology.

[182]  V. Wong,et al.  Ataxia telangiectasia in Chinese children A clinical and electrophysiological study , 1987, Clinical Neurology and Neurosurgery.

[183]  M. Skolnick,et al.  The incidence and gene frequency of ataxia-telangiectasia in the United States. , 1986, American journal of human genetics.

[184]  M. Swift,et al.  Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. , 1986, Journal of the National Cancer Institute.

[185]  B. Dutrillaux,et al.  Probable involvement of immunoglobulin superfamily genes in most recurrent chromosomal rearrangements from ataxia telangiectasia , 1986, Human Genetics.

[186]  R. Teplitz,et al.  Fetal proteins in ataxia-telangiectasia. , 1982, JAMA.

[187]  T. Sawada,et al.  Plasma levels of carcinoembryonic antigen in patients with ataxia-telangiectasia. , 1978, The Journal of pediatrics.

[188]  T. Waldmann,et al.  Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. , 1972, Lancet.

[189]  A. Sokolenko,et al.  ATM mutation spectrum in Russian children with ataxia-telangiectasia. , 2019, European journal of medical genetics.

[190]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[191]  J. Chaudhuri,et al.  Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair. , 2014, Advances in immunology.

[192]  D. Ellison,et al.  Radiation therapy and adjuvant chemotherapy in a patient with a malignant glioneuronal tumor and underlying ataxia telangiectasia: a case report and review of the literature. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  Qi Zhu,et al.  Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia , 2011, International journal of cancer.

[194]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[195]  R. Gatti,et al.  New mutations, polymorphisms, and rare variants in the ATM gene detected by a novel SSCP strategy , 1999, Human mutation.

[196]  D. Easton.  Cancer Risks in A-T Heterozygotes. , 1994, International journal of radiation biology.